Rezafungin (Rezzayo®). HTA ID: 24007

Assessment Status Rapid Review Complete
HTA ID 24007
Drug Rezafungin
Brand Rezzayo®
Indication Rezafungin (Rezzayo®) is indicated for the treatment of invasive candidiasis in adults.
Assessment Process
Rapid review commissioned 22/03/2024
Rapid review completed 26/03/2024
Rapid review outcome A full HTA is not recommended. The NCPE recommends that rezafungin not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations. February 2025